BE523649A - - Google Patents
Info
- Publication number
- BE523649A BE523649A BE523649DA BE523649A BE 523649 A BE523649 A BE 523649A BE 523649D A BE523649D A BE 523649DA BE 523649 A BE523649 A BE 523649A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- trichomonadicidal
- compound
- vehicle
- acyl radical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000001225 therapeutic Effects 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003349 gelling agent Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 124
- 238000002360 preparation method Methods 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 13
- MIHADVKEHAFNPG-UHFFFAOYSA-N 2-Amino-5-nitrothiazole Chemical compound NC1=NC=C([N+]([O-])=O)S1 MIHADVKEHAFNPG-UHFFFAOYSA-N 0.000 description 11
- 206010046914 Vaginal infection Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 201000008100 vaginitis Diseases 0.000 description 10
- 241000224527 Trichomonas vaginalis Species 0.000 description 9
- 210000001215 Vagina Anatomy 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 241000224526 Trichomonas Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 4
- UJRRDDHEMZLWFI-UHFFFAOYSA-N N-(5-nitro-1,3-thiazol-2-yl)acetamide Chemical compound CC(=O)NC1=NC=C([N+]([O-])=O)S1 UJRRDDHEMZLWFI-UHFFFAOYSA-N 0.000 description 4
- 229940116362 Tragacanth Drugs 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000973 chemotherapeutic Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 240000005781 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- DZKKRHBAMGNRCD-UHFFFAOYSA-N N-(5-nitro-1,3-thiazol-2-yl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)NC1=NC=C([N+]([O-])=O)S1 DZKKRHBAMGNRCD-UHFFFAOYSA-N 0.000 description 2
- JKXJETCCPVNCSS-UHFFFAOYSA-N N-(5-nitro-1,3-thiazol-2-yl)propanamide Chemical compound CCC(=O)NC1=NC=C([N+]([O-])=O)S1 JKXJETCCPVNCSS-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- -1 isobutynyl Chemical group 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- TYTYIUANSACAEM-UHFFFAOYSA-M silver;2,4,6-trinitrophenolate Chemical compound [Ag+].[O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O TYTYIUANSACAEM-UHFFFAOYSA-M 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- KANJSWOVFIVFDI-UHFFFAOYSA-N 2,6-diiodocyclohexa-2,5-diene-1,4-dione Chemical compound IC1=CC(=O)C=C(I)C1=O KANJSWOVFIVFDI-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- STPILERHIMWSMC-UHFFFAOYSA-N C(C)(=O)C=1SC(=C(N=1)N)[N+](=O)[O-] Chemical class C(C)(=O)C=1SC(=C(N=1)N)[N+](=O)[O-] STPILERHIMWSMC-UHFFFAOYSA-N 0.000 description 1
- 210000003756 Cervix Mucus Anatomy 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 210000004392 Genitalia Anatomy 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- AFGXQBZUGLBRNH-UHFFFAOYSA-N N-(5-nitro-1,3-thiazol-2-yl)butanamide Chemical compound CCCC(=O)NC1=NC=C([N+]([O-])=O)S1 AFGXQBZUGLBRNH-UHFFFAOYSA-N 0.000 description 1
- YRLOBRGEGAIJJY-UHFFFAOYSA-N N-(5-nitro-1,3-thiazol-2-yl)hexanamide Chemical compound CCCCCC(=O)NC1=NC=C([N+]([O-])=O)S1 YRLOBRGEGAIJJY-UHFFFAOYSA-N 0.000 description 1
- HAQCGFVINUGJBS-UHFFFAOYSA-N N-(5-nitro-1,3-thiazol-2-yl)pentanamide Chemical compound CCCCC(=O)NC1=NC=C([N+]([O-])=O)S1 HAQCGFVINUGJBS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 210000002640 Perineum Anatomy 0.000 description 1
- 229940096826 Phenylmercuric Acetate Drugs 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M Phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 206010046901 Vaginal discharge Diseases 0.000 description 1
- 206010046916 Vaginal inflammation Diseases 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960005130 niridazole Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- TZMFJUDUGYTVRY-UHFFFAOYSA-N pentane-2,3-dione Chemical group CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical class C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE523649A true BE523649A (de) |
Family
ID=158519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE523649D BE523649A (de) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE523649A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006053170A1 (en) * | 2004-11-12 | 2006-05-18 | Kimberly-Clark Worldwide, Inc. | Sugars and/or sugar alcohols for inhibiting and/or treating vaginal infection |
-
0
- BE BE523649D patent/BE523649A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006053170A1 (en) * | 2004-11-12 | 2006-05-18 | Kimberly-Clark Worldwide, Inc. | Sugars and/or sugar alcohols for inhibiting and/or treating vaginal infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0316993B1 (de) | Pharmazeutische Zusammensetzungen mit Gehalt an einem Derivat der 3-Hydroxy-Buttersäure, ausgewählt aus den Oligomeren dieser Säure und den Estern dieser Säure oder dieser Oligomere mit dem 1,3-Butan-diol | |
| FR2833841A1 (fr) | Gel comprenant au moins un retinoide et du peroxyde de benzoyle | |
| FR2651125A1 (fr) | Compositions pharmaceutiques de type "pates a l'eau". | |
| EP1283708B1 (de) | Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments | |
| FR2560523A1 (fr) | Solution ophtalmique contenant du pranoprofene et de l'acide borique | |
| WO1998001118A1 (fr) | Composition pharmaceutique pour administration par voie orale | |
| EP3142687A1 (de) | Antimikrobielle zusammensetzung mit einem kohlenhydrat, glucoseoxydase und zinkoxid | |
| EP0953345A1 (de) | Verwendung von mindestens ein Hydroxystilbene wie ein Mittel zur Verminderung Von Mikro-Organismenhaftvermögen | |
| EP2165704B1 (de) | Verwendung von Alverin zur Behandlung von Hauterkrankungen | |
| EP1343473A1 (de) | Pharmazeutische dronedaron-zusammensetzung für die parenterale verabreichung | |
| CH675356A5 (de) | ||
| BE523649A (de) | ||
| FR2686251A1 (fr) | Composition pour la cicatrisation d'une plaie. | |
| FR2471189A1 (fr) | Procede de preparation d'un agent anti-tumoral comprenant un composant cellulaire de streptococcus pyogenes | |
| CA2493074A1 (fr) | Elevation du taux d'heme oxygenase avec des derives de la rheine | |
| US2988480A (en) | Therapeutically active compositions | |
| WO2019080983A1 (fr) | Nouvelle formulation a base de chitosane et son procede de preparation. | |
| BE1030448B1 (fr) | Complexe glutamine acide - tannique | |
| EP0197876B1 (de) | In der Dermatologie anwendbare und Imidazolidinylurea als aktiven Grundbestandteil enthaltende therapeutische Zusammensetzung | |
| FR2619010A1 (fr) | Composition pharmaceutique antivirale comprenant de la 5-isopropyl-2'-b-deoxyuridine, s'accumulant dans la peau, applicable par voie externe et procede pour sa preparation | |
| FR2903604A1 (fr) | Composition comprenant un retinoide et du peroxyde de benzoyle | |
| EP0404660B1 (de) | Verwendung von Glykoproteinkomplexextrakten aus Gram (-)-Bakterien zur Herstellung eines Arzneimittels zur Erleichterung der Vernarbung der Haut und sein Herstellungsverfahren | |
| FR2933300A1 (fr) | Compositions comprenant au moins une lignane et/ou neolignane en association avec un compose actif contre l'acne | |
| EP1526855A2 (de) | Pharmazeutische zusammensetzungen zur behandlung der harninkontinenz | |
| EP0865289B1 (de) | Arzneizubereitungen enthaltend arctium majus |